Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

USA - NASDAQ:ORMP - US68403P2039 - Common Stock

2.28 USD
-0.08 (-3.39%)
Last: 11/4/2025, 8:00:02 PM
2.2799 USD
0 (0%)
After Hours: 11/4/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, ORMP scores 3 out of 10 in our fundamental rating. ORMP was compared to 192 industry peers in the Pharmaceuticals industry. ORMP has a great financial health rating, but its profitability evaluates not so good. ORMP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ORMP has reported negative net income.
In the past year ORMP has reported a negative cash flow from operations.
In the past 5 years ORMP reported 4 times negative net income.
In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

ORMP's Return On Assets of -14.94% is fine compared to the rest of the industry. ORMP outperforms 63.54% of its industry peers.
With a decent Return On Equity value of -15.64%, ORMP is doing good in the industry, outperforming 70.31% of the companies in the same industry.
Industry RankSector Rank
ROA -14.94%
ROE -15.64%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

9

2. Health

2.1 Basic Checks

ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ORMP has been reduced compared to 1 year ago.
ORMP has more shares outstanding than it did 5 years ago.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ORMP has an Altman-Z score of 6.80. This indicates that ORMP is financially healthy and has little risk of bankruptcy at the moment.
ORMP has a Altman-Z score of 6.80. This is amongst the best in the industry. ORMP outperforms 81.25% of its industry peers.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.8
ROIC/WACCN/A
WACC8.17%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 26.81 indicates that ORMP has no problem at all paying its short term obligations.
ORMP has a Current ratio of 26.81. This is amongst the best in the industry. ORMP outperforms 96.35% of its industry peers.
ORMP has a Quick Ratio of 26.81. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
ORMP has a Quick ratio of 26.81. This is amongst the best in the industry. ORMP outperforms 96.35% of its industry peers.
Industry RankSector Rank
Current Ratio 26.81
Quick Ratio 26.81
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ORMP have decreased strongly by -228.57% in the last year.
The Revenue for ORMP has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.81%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ORMP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.19% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.67%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ORMP. In the last year negative earnings were reported.
Also next year ORMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as ORMP's earnings are expected to decrease with -66.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (11/4/2025, 8:00:02 PM)

After market: 2.2799 0 (0%)

2.28

-0.08 (-3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-05 2025-11-05
Inst Owners17.77%
Inst Owner Change0%
Ins Owners12.36%
Ins Owner Change2.67%
Market Cap93.48M
Revenue(TTM)2.00M
Net Income(TTM)-24162000
Analysts43.33
Price Target3.32 (45.61%)
Short Float %0.6%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)-385.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.74
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.05
BVpS3.77
TBVpS3.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.94%
ROE -15.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.08%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.81
Quick Ratio 26.81
Altman-Z 6.8
F-Score3
WACC8.17%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.81%
EPS Next Y-92.67%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.06%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 3 / 10 to ORMP.


What is the valuation status of ORAMED PHARMACEUTICALS INC (ORMP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Overvalued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORAMED PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ORAMED PHARMACEUTICALS INC (ORMP) is expected to decline by -92.67% in the next year.